RxDoctor Payments DataLook up a doctor →

Asaad Jandali, MD

Pulmonary Disease · Munster, INNPI 1649240276

Payments from drug & device makers

$160,865in general payments, 2019–2025

Across 1,194 payments — averaging $134.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$92K
  • Regeneron Healthcare Solutions, Inc.$19K
  • Viatris Specialty LLC$10K
  • Intuitive Surgical$8K
  • Penumbra, Inc.$4K
  • Verona Pharma, Inc.$4K
  • plus $24K from 54 others

What the payments were for

  • Consulting fees$27,78117%
  • Speaking & faculty fees$89,37556%
  • Travel & lodging$13,0808%
  • Food & beverage$24,83015%
  • Education$5,7994%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Mylan Specialty L.p.214$91,531
Regeneron Healthcare Solutions, Inc.47$18,848
Viatris Specialty LLC15$10,481
Intuitive Surgical18$7,816
Penumbra, Inc.11$4,485
Verona Pharma, Inc.20$4,068
Johnson & Johnson(2 entities)51$2,955
AstraZeneca(2 entities)142$2,725
GSK190$2,334
Sanofi39$2,330
Veran Medical Technologies, Inc.5$1,138
Inari Medical, Inc.6$865
Boehringer Ingelheim46$818
Grifols USA, LLC38$806
Noah Medical Corporation8$790
Jazz Pharmaceuticals Inc.26$749
Actelion Pharmaceuticals US, Inc.23$708
Inspire Medical Systems, Inc.7$606
Abiomed3$494
Electromed, Inc.34$479
Harmony Biosciences LLC16$414
Edwards Lifesciences2$350
United Therapeutics Corporation16$334
Pfizer16$322
Shionogi Inc14$307
Takeda Pharmaceuticals U.S.A., Inc.13$285
Baxter Healthcare16$274
Mallinckrodt Hospital Products Inc.8$262
Amgen13$252
ANI Pharmaceuticals, Inc.8$230
Mallinckrodt Enterprises LLC9$205
Sunovion Pharmaceuticals Inc.14$162
Galvanize Therapeutics, Inc2$157
Novartis8$154
Axsome Therapeutics, Inc.7$147
Genentech USA, Inc.9$137
Medical Device Business Services, Inc.1$130
Pulmonx Corporation2$126
Mylan Pharmaceuticals Inc.1$124
Lilly USA, LLC5$121
Insmed, Inc.7$118
Bayer7$106
Inogen, Inc.5$103
Merck6$102
La Jolla Pharmaceutical Company2$99
Circassia Inc.5$88
Philips North America LLC4$71
Shire North American Group Inc4$62
Mayne Pharma Commercial LLC3$60
Teva Pharmaceuticals USA, Inc.3$59
Paratek Pharmaceuticals, Inc.4$58
Pharming Healthcare, Inc.2$56
Advanced Respiratory, Inc2$56
Chiesi USA, Inc.3$51
Gilead3$47
E.r. Squibb & Sons, L.L.C.2$34
Vapotherm Inc1$32
Nabriva Therapeutics, PLC2$32
Covis Pharma GmbH1$29
CSL Behring2$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$160,865 in reported general payments places this provider in the 95th percentile of 258 pulmonary disease providers in Indiana.

See all pulmonary disease providers in Indiana

Medicare billing

Part B allowed, 2024
$553,656
Medicare patients
1,238
Services billed
9,179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter356$429,108
OfevNintedanib Esylate25$331,466
Breo ElliptaFluticasone/Vilanterol232$164,047
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr174$160,205
OpsumitMacitentan12$131,083
Breztri AerosphereBudesonide/Glycopyr/Formoterol91$82,737
NucalaMepolizumab19$65,447
Spiriva RespimatTiotropium Bromide54$54,282
Dupixent SyringeDupilumab13$47,656
Combivent RespimatIpratropium/Albuterol Sulfate39$35,645
XareltoRivaroxaban32$33,483
XolairOmalizumab12$32,942
Incruse ElliptaUmeclidinium Bromide51$29,773
Albuterol Sulfate HfaAlbuterol Sulfate1,100$23,964
Stiolto RespimatTiotropium Br/Olodaterol Hcl26$21,542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala, Incruse Ellipta$2,334$853,205849 claims
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat$818$442,936144 claims
Actelion Pharmaceuticals US, Inc.Opsumit$708$131,08312 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,725$95,358123 claims
Johnson & JohnsonXarelto$2,955$33,48332 claims
PfizerEliquis$322$10,42718 claims
MerckDulera$102$6,82912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 258 pulmonary disease providers in Indiana.

Other pulmonary disease in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →